Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.

Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT.

Neuro Oncol. 2012 Jun;14(6):790-7. doi: 10.1093/neuonc/nos076. Epub 2012 Apr 3.

2.

Visual acuity of children treated with chemotherapy for optic pathway gliomas.

Kalin-Hajdu E, D├ęcarie JC, Marzouki M, Carret AS, Ospina LH.

Pediatr Blood Cancer. 2014 Feb;61(2):223-7. doi: 10.1002/pbc.24726. Epub 2013 Aug 19.

PMID:
23956233
3.

Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.

Dalla Via P, Opocher E, Pinello ML, Calderone M, Viscardi E, Clementi M, Battistella PA, Laverda AM, Da Dalt L, Perilongo G.

Neuro Oncol. 2007 Oct;9(4):430-7. Epub 2007 Aug 17.

4.

Natural history and outcome of optic pathway gliomas in children.

Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, Rutka J, Buncic JR, Bouffet E.

Pediatr Blood Cancer. 2009 Dec 15;53(7):1231-7. doi: 10.1002/pbc.22198.

PMID:
19621457
5.

Visual outcome following chemotherapy for progressive optic pathway gliomas.

Shofty B, Ben-Sira L, Freedman S, Yalon M, Dvir R, Weintraub M, Toledano H, Constantini S, Kesler A.

Pediatr Blood Cancer. 2011 Sep;57(3):481-5. doi: 10.1002/pbc.22967. Epub 2011 Jan 16.

PMID:
21241008
6.

Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.

Avery RA, Bouffet E, Packer RJ, Reginald A.

Invest Ophthalmol Vis Sci. 2013 Feb 5;54(2):1034-8. doi: 10.1167/iovs.12-11385.

PMID:
23329671
7.

Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas.

Kelly JP, Leary S, Khanna P, Weiss AH.

Ophthalmology. 2012 Jun;119(6):1231-7. doi: 10.1016/j.ophtha.2011.12.035. Epub 2012 Feb 25.

PMID:
22364864
8.

Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive.

Dodgshun AJ, Elder JE, Hansford JR, Sullivan MJ.

Cancer. 2015 Dec 1;121(23):4190-6. doi: 10.1002/cncr.29649. Epub 2015 Aug 17.

9.

Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.

Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC.

J AAPOS. 2010 Apr;14(2):155-8. doi: 10.1016/j.jaapos.2009.11.020.

PMID:
20451859
10.

Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1.

Campagna M, Opocher E, Viscardi E, Calderone M, Severino SM, Cermakova I, Perilongo G.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1083-8. doi: 10.1002/pbc.22748.

PMID:
20979170
11.

Extensive central nervous system involvement in optic pathway gliomas in neurofibromatosis type 1.

Shaikh F, Johnston D, Michaud J, Hurteau J, Vassilyadi M, Keene D.

Pediatr Blood Cancer. 2011 Oct;57(4):688-6690. doi: 10.1002/pbc.23143. Epub 2011 Apr 4.

PMID:
21465640
12.

Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.

de Blank PM, Berman JI, Liu GT, Roberts TP, Fisher MJ.

Neuro Oncol. 2013 Aug;15(8):1088-95. doi: 10.1093/neuonc/not068. Epub 2013 May 7.

13.

Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients.

Thiagalingam S, Flaherty M, Billson F, North K.

Ophthalmology. 2004 Mar;111(3):568-77. Review.

PMID:
15019338
14.

Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA.

J Neuroophthalmol. 2017 Sep;37 Suppl 1:S23-S32. doi: 10.1097/WNO.0000000000000550. Review.

PMID:
28806346
15.

Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

King A, Listernick R, Charrow J, Piersall L, Gutmann DH.

Am J Med Genet A. 2003 Oct 1;122A(2):95-9.

PMID:
12955759
16.

Follow-up of optic pathway gliomas in children with neurofibromatosis type 1.

Kuenzle C, Weissert M, Roulet E, Bode H, Schefer S, Huisman T, Landau K, Boltshauser E.

Neuropediatrics. 1994 Dec;25(6):295-300.

PMID:
7770126
17.

The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.

Prada CE, Hufnagel RB, Hummel TR, Lovell AM, Hopkin RJ, Saal HM, Schorry EK.

J Pediatr. 2015 Oct;167(4):851-856.e1. doi: 10.1016/j.jpeds.2015.07.001. Epub 2015 Jul 29.

PMID:
26233602
18.

Neurofibromatosis type 1 and sporadic optic gliomas.

Singhal S, Birch JM, Kerr B, Lashford L, Evans DG.

Arch Dis Child. 2002 Jul;87(1):65-70.

19.

The role of surgery in optic pathway/hypothalamic gliomas in children.

Goodden J, Pizer B, Pettorini B, Williams D, Blair J, Didi M, Thorp N, Mallucci C.

J Neurosurg Pediatr. 2014 Jan;13(1):1-12. doi: 10.3171/2013.8.PEDS12546. Epub 2013 Oct 18.

PMID:
24138145
20.

Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.

Balcer LJ, Liu GT, Heller G, Bilaniuk L, Volpe NJ, Galetta SL, Molloy PT, Phillips PC, Janss AJ, Vaughn S, Maguire MG.

Am J Ophthalmol. 2001 Apr;131(4):442-5.

PMID:
11292406

Supplemental Content

Support Center